Related Experiment Video
Updated: Jul 19, 2025
10:03
Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
Published on: August 16, 2020
10.7K
Lewy Body Dementia: An Overview of Promising Therapeutics
Irina A Skylar-Scott1, Sharon J Sha2
1Memory Disorders Division, Department of Neurology and Neurological Sciences, Stanford University School of Medicine, 213 Quarry Road, Palo Alto, CA, 94305, USA. iskylarscott@stanford.edu.
Current Neurology and Neuroscience Reports
|August 12, 2023
Summary
This review explores new treatments for Lewy body dementia (LBD), focusing on disease-modifying therapies and symptomatic options for cognitive issues and psychosis. Promising trials are underway for LBD patients and caregivers.
Area of Science:
- Neuroscience
- Pharmacology
- Geriatrics
Background:
- Lewy body dementia (LBD) includes dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD).
- Non-motor symptoms like cognitive impairment and psychosis significantly burden LBD patients and caregivers.
Purpose of the Study:
- To review potential disease-modifying therapies (DMTs) for LBD.
- To evaluate investigative symptomatic treatments for cognitive impairment and psychosis in LBD.
Main Methods:
- Comprehensive review of prospective disease-modifying therapies (DMTs) with available clinical trial data.
- Appraisal of symptomatic therapies for cognitive impairment and psychosis in LBD.
Main Results:
- Eleven prospective DMTs are under investigation, with some having Phase 2 data (e.g., neflamapimod, nilotinib).
- Limited data exists for other DMTs in symptomatic populations (e.g., ambroxol, clenbuterol).
- NYX-458 shows promise for cognitive impairment; pimavanserin is promising for psychosis in LBD.
Conclusions:
- Despite challenges, ongoing and upcoming trials indicate progress in developing novel therapeutics for LBD.
- Further research is crucial for effective disease-modifying and symptomatic treatments for LBD.
Related Concept Videos
01:15Parkinson's Disease: Overview
598
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
598
01:24Parkinson's Disease: Treatment
299
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
299
01:22Alzheimer's Disease: Treatment
215
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
215
01:26Alzheimer's Disease: Overview
521
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
521
01:30Dementia
139
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
139
01:28Drug Therapy
69
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
69